(Q36577189)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

François Mach

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Nephrology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

378-387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

What do the statins tell us?

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statin Use Is Associated with Improved Function and Survival of Lung Allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Impact of statin treatment on 1-year functional and histologic renal allograft outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The effects of lipid-lowering agents on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statins: the new aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The Ras superfamily at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Regulation of cytokine signaling and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

A novel anti-inflammatory role for simvastatin in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Therapy with statins in patients with refractory rheumatic diseases: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Direct Anti-Inflammatory Mechanisms Contribute to Attenuation of Experimental Allograft Arteriosclerosis by Statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statin use after renal transplantation: a systematic quality review of trial-based evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Beyond lipid-lowering: effects of statins on endothelial nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Impact of dyslipidaemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Understanding the nature of renal disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of combining ACE inhibitor and statin in severe experimental nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Simvastatin protection against acute immune-mediated glomerulonephritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Postischemic acute renal failure is reduced by short-term statin treatment in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Atorvastatin improves the course of ischemic acute renal failure in aging rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Expression of fibronectin splice variants in the postischemic rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of pravastatin in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Biomarkers of inflammation and progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Comparative pharmacology of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Rosuvastatin: a review of its use in the management of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Safety and efficacy of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Dangers of rosuvastatin identified before and after FDA approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Why do we need a statin trial in hemodialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Effect of atorvastatin and pravastatin on serum C-reactive protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in pri

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Should rosuvastatin be withdrawn from the market?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0217

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference